CN113846159A - Special chip for detecting expression of breast cancer related gene - Google Patents
Special chip for detecting expression of breast cancer related gene Download PDFInfo
- Publication number
- CN113846159A CN113846159A CN202110110056.2A CN202110110056A CN113846159A CN 113846159 A CN113846159 A CN 113846159A CN 202110110056 A CN202110110056 A CN 202110110056A CN 113846159 A CN113846159 A CN 113846159A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- probe
- special chip
- artificial sequence
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Abstract
The invention relates to a special chip for detecting breast cancer related gene expression, which takes a pair of primers of RT-PCR reaction as a probe pair to be fixed on a substrate, utilizes the gene chip to complete simultaneous detection of multiple gene expression profiles at one time, and can rapidly complete detection of breast cancer specific gene expression conditions by utilizing an RNA sample.
Description
Technical Field
The invention relates to the field of biochips, in particular to a special chip for detecting breast cancer related gene expression.
Background
The biochip technology has been widely applied to clinical disease diagnosis, health management, drug research and development, animal and plant quarantine, food detection, environmental monitoring, scientific research, forensic detection and other fields, and has wide application prospect and great market demand.
The gene chip is one kind of biochip, which is prepared through planting serial probes with known sequence on the chip substrate, and may be used in the hybridization detection of specific mark nucleic acid and reporting the nucleic acid information in the detected object through identification and information processing.
New cancer cases occur in 1929 in the world in 2020, wherein 1006 ten thousand cases are male, 923 ten thousand cases are female; 996 ten thousand cases of cancer death worldwide in 2020, of which 553 thousand in men and 443 ten thousand in women. The number of new cases of breast cancer reaches 226 ten thousand, and exceeds 220 ten thousand of lung cancer, and the breast cancer replaces the lung cancer, becomes the first cancer in the world, and becomes the first killer threatening the life of women.
Currently, the detection of breast cancer is mainly based on imaging and immunohistochemistry, assisted by gene sequencing based on instruments and equipment, and simultaneously, the expression profile analysis and adjuvant drug analysis of breast cancer-related genes are performed by quantitative PCR, such as: the expression level of the breast cancer 21 gene is used for judging the prognosis condition of a patient, whether auxiliary chemotherapy is needed or not is determined according to the detection result, and whether endocrine auxiliary treatment can be performed by using tamoxifen or not is determined.
The current main method is to extract RNA from a tissue slice of a patient, a series of complex operations such as dehydration, hydration and the like are required to be completed to obtain the purified RNA, the obtained RNA is respectively added into each PCR tube according to a test target, each PCR tube completes quantitative PCR reaction of one gene (RNA), the operation is very complicated, and the RNA can be completed by professional staff, so that the automation integration is inconvenient.
Disclosure of Invention
The invention aims to solve the defects in the prior art, utilizes an enzymatic synthesis technology of nucleic acid synthesis in a biological system, converts RNA information of a tumor into an extended chain sequence of a probe through DNA polymerase, completes all detection processes on one chip, can complete the detection of the expression condition of breast cancer related genes in one step by automation of the detection, and provides an effective judgment basis for the prognosis judgment and subsequent treatment of the breast cancer.
The invention has the following inventive concept: the primers for amplifying the target RNA are fixed on the substrate, so that a plurality of RNAs can be amplified synchronously; meanwhile, DNA polymerase is used for converting and integrating RNA sequence information into the extended strand of the probe, and the related information of the RNA can be obtained by detecting the extended strand of the probe; finally, the Click is used to mark dNTP(s) integrated into the probe extension chain, so as to obtain the position of the probe (positive result) for completing the PCR reaction and convert to obtain the RNA expression level of the breast cancer related gene.
In order to solve the problems, the technical scheme of the invention is as follows: a special chip for detecting breast cancer related gene expression is characterized by comprising the following steps:
s1 screening genes related to breast cancer occurrence and genes related to breast cancer prognosis according to the related breast cancer guide, selecting a pair of probes for each gene according to the specific mRNA sequence of each gene, and ensuring that the group of probes can complete RT-PCR amplification of the specific mRNA sequence;
s2, completing chemical synthesis of probe pairs, and simultaneously ensuring that a connecting arm is added at the 5' tail end of each probe;
s3, mixing each group of probe pairs together, and fixing each probe on a substrate through a covalent bond via a connecting arm to manufacture a special chip capable of detecting the expression of the breast cancer related gene;
s4, adding the total RNA to be detected to a special chip, assembling an RT-PCR amplification system on the special chip, combining a specific mRNA sequence with a probe matched with the specific mRNA sequence, starting RT-PCR amplification, and converting specific mRNA sequence information into a probe extension chain;
s5, after finishing RT-PCR amplification, fully washing to remove various components of the RT-PCR reaction system on the special chip, ensuring that only the probe and the probe extension chain are on the special chip, and ensuring that the detection system has no background interference;
s6 in the RT-PCR reaction system, using the marked dNTP as the substrate, integrating the marked dNTP in the probe extension chain in the RT-PCR reaction process, and finally obtaining the detection result of the special chip for the breast cancer related gene expression based on the signal of the marked dNTP and the sample application position of each group of probe pairs.
Preferably, a specific mRNA sequence is detected by directly performing an RT-PCR amplification reaction using a pair of primers (probe pairs) immobilized on a chip.
Preferably, the RT-PCR amplification reaction is completed on a very small chip, and is not required to be divided into a plurality of PCR tubes, one chip can simultaneously complete hundreds of detections, and a fixed pair of primers (probe pairs) does not influence the RT-PCR reaction of another pair of primers (probe pairs).
Preferably, one nucleotide substrate of the RT-PCR amplification reaction is a labeled dNTP which is integrated into the extension strand of the probe during the RT-PCR amplification reaction.
Preferably, the labeled dNTPs do not affect the extension of the probe strand by the action of the DNA polymerase, and can further complete detectable signal modification.
Preferably, the number of labeled dNTPs that can be incorporated into each probe extension strand is quantitatively calculated from the target mRNA sequence.
Preferably, the labeled dNTPs on the probe extension chain can complete detectable information modification by utilizing a Click reaction, and further complete analysis of related indexes of the breast cancer through the copy number ratio of mRNA of genes corresponding to fluorescence intensity of each site.
Compared with the prior art, the special chip for detecting the expression of the breast cancer related genes can simultaneously detect tens of thousands of gene expression profiles on one chip, can finish the rapid detection of a small sample amount, is very convenient for the expression screening of the breast cancer related genes, can realize the multiple screening with low cost, and can find the expression change of the breast cancer genes and treat the breast cancer genes in time. In the invention, dNTP capable of generating signals is integrated into the probe extension chain, the label is stable, quantitative analysis can be realized, the inconvenience that fluorescence detection is required for each amplification in the traditional quantitative PCR is not needed, and the signals are obtained once after the reaction is finished, so that the detection time is effectively shortened.
Detailed Description
The present invention is further described in detail below with reference to specific examples. The following examples are illustrative only, not limiting, and are not intended to limit the scope of the invention. The chemical reagents and instruments used in the present invention are commercially available without specific reference.
Example 1
A special chip for detecting breast cancer related gene expression is characterized by comprising the following steps:
s1 corresponding amplification primers were designed according to the mature mRNA sequence of the breast cancer 21 gene as specified in the breast cancer guidelines, as specified in the following Table:
TABLE 1 primer for detecting expression of Breast cancer 21 Gene
Screening genes related to breast cancer occurrence and genes related to breast cancer prognosis according to a breast cancer treatment related guide, selecting a pair of probes for each gene according to a specific mRNA sequence of each gene, and ensuring that the group of probes can complete RT-PCR amplification of the specific mRNA sequence;
s2, completing chemical synthesis of probe pairs, and simultaneously ensuring that a connecting arm formed by 6 ethylene glycol polymer chains is added at the 5' tail end of each probe, and the tail end is connected and modified with an amino group for connecting with a substrate;
s3, mixing a group of probes for amplifying specific mRNA sequences of the same gene to form probe pairs, fixing the probe pairs on a substrate by amino groups, ensuring that each group of probe pairs is fixed on the substrate in a covalent bond mode through a connecting arm, recording the corresponding relation between the positions of the probes and the sequences of the probe pairs, and manufacturing a special chip capable of detecting the expression of the breast cancer 21 gene;
s4 total RNA is obtained by using a sample obtained by micro-needle puncture and adding the total RNA to a special chip capable of detecting breast cancer 21 gene expression by using a special kit (Saimerfi), an RT-PCR amplification system (related RT-PCR is purchased from Saimerfi) is assembled on the special chip, wherein one dNTP substrate is ethinyl-labeled uridine (EdU) deoxyribose triphosphate, a specific mRNA sequence is combined with a matched probe and starts RT-PCR amplification, specific mRNA sequence information is converted into an extension chain (cDNA) by using the probe as a primer, and the EdU enters the probe extension chain according to the corresponding thymine nucleotide position;
s5, after finishing RT-PCR amplification, fully washing to remove various components of the RT-PCR reaction system on the special chip, ensuring that only the probe and the probe extension chain are on the special chip, and ensuring that the detection system has no background interference;
s6 in the RT-PCR reaction system, the marked EdU is integrated in the probe extension chain in the RT-PCR reaction process, the EdU can utilize Click reaction to complete fluorescence marking, all the EdU in each probe extension chain can be directly marked with fluorescence molecules (such as cy3) on the chip, and because each EdU base on the probe extension chain is marked with cy3 molecules, the fluorescence signal of the probe is greatly improved, and the positive signal detection efficiency is effectively improved;
s7, judging the qualitative expression of the specific gene of breast cancer according to the position information of the probe and the existence of the fluorescent signal, completing the conversion of the fluorescent signal according to the specific RNA sequence and the corresponding probe pair sequence, and performing the copy number comparison analysis of different mRNA; s8 calculation formula for RS score using breast cancer guide, see Table below
RS score calculation
RS score calculation is carried out, and a reference basis can be provided for breast cancer prognosis judgment.
The above description is only for the purpose of creating a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can substitute or change the technical solution and the inventive concept of the present invention within the technical scope of the present invention.
Sequence listing
<110> Beijing Baionano core Biotechnology Ltd
<120> a special chip for detecting breast cancer related gene expression
<160> 42
<170> SIPOSequenceListing 1.0
<210> 1
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
agcgcggcta cagcttcacc ac 22
<210> 2
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
ggcagcggaa ccgctcattg cc 22
<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
aggcaatgag aagcacgacc tt 22
<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
gcgacaagag tgaaacttcg tc 22
<210> 5
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
cacctgacgc ccttcaccgc gc 22
<210> 6
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
tcatccacag ggcgatgttg tccac 25
<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gctttgatgc aaatattgtc tagtc 25
<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
tgccatacac acaagataca ttgtc 25
<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
gatgcaagac agcggatgaa ag 22
<210> 10
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
gcattaagtt acttgaactc actcac 26
<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
ggaagcaact aaatcataag aatgc 25
<210> 12
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
ctctgtggat aactgccatg tcc 23
<210> 13
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
gctgctcatg gtggtgcacg aag 23
<210> 14
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
ttctcacacc gctgtgttcc atcc 24
<210> 15
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
ggacctctcg acctcaagct ctc 23
<210> 16
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
agacagggcc tgcataccca cc 22
<210> 17
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
gtacaaccac catgacaact gc 22
<210> 18
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
agttccccca gtcctgccat g 21
<210> 19
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
ccaggaggta gatggtagtg atcaag 26
<210> 20
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
aacggagatg ggccccacag tt 22
<210> 21
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
ctgagacatt ctccacccgc g 21
<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
tcgggctgcc agatagagtc 20
<210> 23
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 23
gagcctggct gtggggaaag tg 22
<210> 24
<211> 28
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 24
gtctgtacat atatctttat tttcatac 28
<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 25
ctgccacatc tgagtcggcc tg 22
<210> 26
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 26
cttctctaca aagccaatta ctaagc 26
<210> 27
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 27
ctcctgaata acatctaaca tctag 25
<210> 28
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 28
ctttgtaagt ccttgattta ccatg 25
<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 29
tttcatgcag gagaaagccc gg 22
<210> 30
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 30
ggtcacctga atgactctca gattc 25
<210> 31
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 31
agctgacctt gagttctggc cttatt 26
<210> 32
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 32
ctcctggcct tcaaggccct act 23
<210> 33
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 33
ggcctgtaat cccagctact tgg 23
<210> 34
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 34
gtctggctct gtcgcccagg ct 22
<210> 35
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 35
cttgtctatt tcctgtatcc tgct 24
<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 36
tgattctgag gatttctgat gg 22
<210> 37
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 37
agaaggtggt gaagcaggcg tc 22
<210> 38
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 38
gccacatacc aggaaatgag cttg 24
<210> 39
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 39
tgatcaagac tggagacaaa gt 22
<210> 40
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 40
gaagcgagaa tgcagagttt cc 22
<210> 41
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 41
cagagggact ttgtatagaa ggtt 24
<210> 42
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 42
ctatgacaaa cagctgatca tcac 24
Claims (8)
1. A special chip for detecting breast cancer related gene expression is characterized by comprising the following steps:
s1 screening genes related to breast cancer occurrence and genes related to breast cancer prognosis according to the related breast cancer guide, selecting a pair of probes for each gene according to the specific mRNA sequence of each gene, and ensuring that the group of probes can complete RT-PCR amplification of the specific mRNA sequence;
s2, completing chemical synthesis of probe pairs, and simultaneously ensuring that a connecting arm is added at the 5' tail end of each probe;
s3, mixing each group of probe pairs together, and fixing each probe on a substrate through a covalent bond via a connecting arm to manufacture a special chip capable of detecting the expression of the breast cancer related gene;
s4, adding the total RNA to be detected to a special chip, assembling an RT-PCR amplification system on the special chip, combining a specific mRNA sequence with a probe matched with the specific mRNA sequence, starting RT-PCR amplification, and converting specific mRNA sequence information into a probe extension chain;
s5, after finishing RT-PCR amplification, fully washing to remove various components of the RT-PCR reaction system on the special chip, ensuring that only the probe and the probe extension chain are on the special chip, and ensuring that the detection system has no background interference;
s6 in the RT-PCR reaction system, using the marked dNTP as the substrate, integrating the marked dNTP in the probe extension chain in the RT-PCR reaction process, and finally obtaining the detection result of the special chip for the breast cancer related gene expression based on the signal of the marked dNTP and the sample application position of each group of probe pairs.
2. The special chip for detecting the expression of breast cancer-related genes as claimed in claim 1, wherein a pair of primers (probe pairs) fixed on the chip is used to directly perform RT-PCR amplification reaction to detect specific mRNA sequences.
3. The special chip for detecting breast cancer-related gene expression as claimed in claim 1, wherein RT-PCR amplification reaction is performed on a very small chip without dividing into several PCR tubes, one chip can perform hundreds of detections simultaneously, and a fixed pair of primers (probe pairs) does not affect RT-PCR reaction of another pair of primers (probe pairs).
4. The special chip for detecting expression of breast cancer-related genes as claimed in claim 1, wherein a nucleotide substrate of RT-PCR amplification reaction is a labeled dNTP as a substrate, and the labeled dNTP is integrated into the extension chain of the probe during the RT-PCR amplification reaction.
5. The method of claim 4, wherein the labeled dNTP is a substrate, and wherein the labeled dNTP does not affect the extension of the probe strand by the action of DNA polymerase, and further performs a detectable signal modification.
6. The special chip for detecting the expression of breast cancer-related genes as claimed in claim 1, wherein the quantity of labeled dNTPs that can be integrated on each probe extension strand can be quantitatively calculated according to the target mRNA sequence.
7. The special chip for detecting the expression of the breast cancer related gene as claimed in claim 1, wherein the labeled dNTPs on the probe extension chain can use Click reaction to complete detectable information modification, and can further complete the analysis of the breast cancer related index by the copy number ratio of mRNA of the gene corresponding to the fluorescence intensity of each site.
8. Protects the application of the special chip for detecting the expression of the breast cancer related gene in the fields related to the breast cancer screening and prognosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110110056.2A CN113846159B (en) | 2021-01-27 | 2021-01-27 | Special chip for detecting expression of breast cancer related gene |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110110056.2A CN113846159B (en) | 2021-01-27 | 2021-01-27 | Special chip for detecting expression of breast cancer related gene |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113846159A true CN113846159A (en) | 2021-12-28 |
CN113846159B CN113846159B (en) | 2023-04-07 |
Family
ID=78972196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110110056.2A Active CN113846159B (en) | 2021-01-27 | 2021-01-27 | Special chip for detecting expression of breast cancer related gene |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113846159B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116790724A (en) * | 2023-06-27 | 2023-09-22 | 北京百奥纳芯生物科技有限公司 | Method for detecting single base difference and gene chip |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067492A1 (en) * | 2002-10-04 | 2004-04-08 | Allan Peng | Reverse transcription on microarrays |
US20040208792A1 (en) * | 2002-12-20 | 2004-10-21 | John Linton | Assay apparatus and method using microfluidic arrays |
CN1557964A (en) * | 2004-01-19 | 2004-12-29 | 中国科学院上海微系统与信息技术研究 | In-situ polymerase chain reaction approach for detecting target gene on chip |
CN101008034A (en) * | 2006-12-13 | 2007-08-01 | 南开大学 | Breast carcinoma transfer related gene chip establishment and its establishing method |
CN101921858A (en) * | 2010-08-23 | 2010-12-22 | 广州益善生物技术有限公司 | Liquid phase chip for detecting breast cancer prognosis-related gene mRNA expression level |
CN102337327A (en) * | 2010-07-21 | 2012-02-01 | 其昌達生物高科技(上海)有限公司 | 28-gene array detection system for breast cancer prognosis |
WO2012162779A1 (en) * | 2011-05-27 | 2012-12-06 | The University Of British Columbia | Microfluidic cell trap and assay apparatus for high-throughput analysis |
CN106977498A (en) * | 2017-03-29 | 2017-07-25 | 华南师范大学 | Intracellular Fluorescence response flag DNA luminous point hits probe and preparation method and application |
CN107058523A (en) * | 2017-03-21 | 2017-08-18 | 温州迪安医学检验所有限公司 | A kind of genetic test primer of breast carcinoma recurring risk assessment 21 and its application |
US20190119725A1 (en) * | 2014-04-14 | 2019-04-25 | W2 Biosolutions, Llc | Nucleic Acid Quantification Method |
CN110129435A (en) * | 2019-02-22 | 2019-08-16 | 深圳塔歌生物技术有限公司 | 21 gene Multiple detection kit of breast cancer |
-
2021
- 2021-01-27 CN CN202110110056.2A patent/CN113846159B/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067492A1 (en) * | 2002-10-04 | 2004-04-08 | Allan Peng | Reverse transcription on microarrays |
US20040208792A1 (en) * | 2002-12-20 | 2004-10-21 | John Linton | Assay apparatus and method using microfluidic arrays |
CN1557964A (en) * | 2004-01-19 | 2004-12-29 | 中国科学院上海微系统与信息技术研究 | In-situ polymerase chain reaction approach for detecting target gene on chip |
CN101008034A (en) * | 2006-12-13 | 2007-08-01 | 南开大学 | Breast carcinoma transfer related gene chip establishment and its establishing method |
CN102337327A (en) * | 2010-07-21 | 2012-02-01 | 其昌達生物高科技(上海)有限公司 | 28-gene array detection system for breast cancer prognosis |
CN101921858A (en) * | 2010-08-23 | 2010-12-22 | 广州益善生物技术有限公司 | Liquid phase chip for detecting breast cancer prognosis-related gene mRNA expression level |
WO2012162779A1 (en) * | 2011-05-27 | 2012-12-06 | The University Of British Columbia | Microfluidic cell trap and assay apparatus for high-throughput analysis |
US20190119725A1 (en) * | 2014-04-14 | 2019-04-25 | W2 Biosolutions, Llc | Nucleic Acid Quantification Method |
CN107058523A (en) * | 2017-03-21 | 2017-08-18 | 温州迪安医学检验所有限公司 | A kind of genetic test primer of breast carcinoma recurring risk assessment 21 and its application |
CN106977498A (en) * | 2017-03-29 | 2017-07-25 | 华南师范大学 | Intracellular Fluorescence response flag DNA luminous point hits probe and preparation method and application |
CN110129435A (en) * | 2019-02-22 | 2019-08-16 | 深圳塔歌生物技术有限公司 | 21 gene Multiple detection kit of breast cancer |
Non-Patent Citations (4)
Title |
---|
FREDERICK L BAEHNER: "The analytical validation of the Oncotype DX Recurrence Score assay", 《ECANCER》 * |
W. RUSS ALGAR等: "《Chemoselective and Bioorthogonal Ligation Reactions》", 1 March 2017, WILEY-VCH VERLAG GMBH & CO * |
唐金海等: "实时定量RT-PCR芯片技术筛选乳腺癌术后复发相关基因", 《中国肿瘤外科杂志》 * |
夏邦顺,何蕴韶主编: "《临床分子诊断学》", 31 July 2012, 中山大学出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116790724A (en) * | 2023-06-27 | 2023-09-22 | 北京百奥纳芯生物科技有限公司 | Method for detecting single base difference and gene chip |
CN116790724B (en) * | 2023-06-27 | 2024-04-12 | 北京百奥纳芯生物科技有限公司 | Method for detecting single base difference and gene chip |
Also Published As
Publication number | Publication date |
---|---|
CN113846159B (en) | 2023-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101424640B (en) | Method for detecting miRNA in blood serum, detection kit, biochip, making method thereof and application method | |
JP6404714B2 (en) | Multivariate diagnostic assay and method for using the same | |
CN109207579A (en) | A kind of Multiple detection kit and application thereof detecting malignant fever tumor susceptibility gene | |
CN100588953C (en) | Method for detecting mononucleotide polymorphism with biochip | |
CN111004862B (en) | Primer and probe for rapidly detecting and identifying cryptococcus and application thereof | |
CN113481286B (en) | MiRNA-208a amplification primer pair based on strand exchange amplification and detection kit thereof | |
CN101988061A (en) | Breast cancer detecting marker as well as detecting method, kit and biological chip thereof | |
CN101570784B (en) | Signal combination coding-based DNA ligation sequencing method | |
CN114134219A (en) | Multiple nucleic acid detection system and preparation method and application thereof | |
CN108660215B (en) | Application of reagent for detecting circMAN1A2 and circRNF13 and kit | |
CN109593847B (en) | Primer pair, kit and method for detecting stability of NR24 locus of microsatellite | |
CN114369656B (en) | Molecular marker for auxiliary diagnosis of tubercular meningitis, application thereof and kit | |
CN113846159B (en) | Special chip for detecting expression of breast cancer related gene | |
CN106555004B (en) | The lncRNA markers of cerebral arterial thrombosis | |
KR102414106B1 (en) | Multiple biomarkers for diagnosis of breast cancer and Uses thereof | |
CN108642164A (en) | MiRNA capture probes, separation expand integrated detection method and detection kit | |
CN112280867A (en) | Early warning method for liver cancer, detection kit for early warning and detection method | |
JP5932778B2 (en) | Method and kit for distinguishing breast cancer from benign breast disease | |
CN111334568A (en) | Multiple connection probe amplification probe combination and kit for screening congenital heart disease gene copy number variation and susceptible persons | |
CN108660213B (en) | Application of reagent for detecting three non-coding RNAs and kit | |
CN110358810A (en) | A kind of bioprobe detecting miRNA and detection method and purposes | |
CN108588218A (en) | A kind of minimally invasive detection kit of serum miRNA combination | |
CN108823308B (en) | Application of reagent for detecting circMAN1A2 and LOC284454 and kit | |
CN109593835B (en) | Method, kit and application for evaluating trace FFPE RNA sample | |
JP7191984B2 (en) | Analysis method and kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |